Trial · NCT02429453

FFP Versus PCC in Intracranial Hemorrhage

NCT02429453, Not applicable, Withdrawn, University of Utah

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. FFP Versus PCC in Intracranial Hemorrhage. Trials, record NCT02429453. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02429453

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: FFP Versus PCC in Intracranial Hemorrhage
NCT number: NCT02429453
Status: Withdrawn
Phases: Not applicable
Enrollment: 0 participants, actual
Lead sponsor: University of Utah
Conditions: Intracranial Hemorrhage, Traumatic, Intracranial Hemorrhage, Spontaneous
Interventions: Four Factor Prothrombin Complex Concentrate, Fresh Frozen Plasma
First posted: 2015-04-29
Last updated: 2016-11-16

Source ClinicalTrials.gov

Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Rapid reversal of warfarin as measured by international normalized ratio (INR) drawn at 30 minutes after transfusion	30 minutes after transfusion completion	INR level 30 minutes after transfusion completion of FFP or 4 factor prothrombin complex concentrate
Secondary	Radiographic expansion of traumatic intracerebral hemorrhage as measured by CT scan within 24 hours of presentation	24 hours after presentation	Expansion of blood on repeat CT scan of \>10%
Secondary	Timing of reversal of warfarin as measured by INR drawn at 3 hours, 8 hours and 24 hours after transfusion	3-24 hours after completion of FFP or 4 factor prothrombin complex concentrate transfusion	INR level at 3 hours, 8 hours and 24 hours after transfusion completion of FFP or prothrombin complex concentrate
Secondary	Thromboelastography response as measured by results of ROTEM analysis at 30 minutes and 24 hours after transfusion	30 minutes and 24 hours after completion of FFP or 4 factor prothrombin complex concentrate transfusion	Results of ROTEM analysis at 30 minutes and 24 hours after transfusion
Secondary	Absolute INR reversal as measured by INR drawn 24 hours after transfusion	24 hours after completion of FFP or 4 factor prothrombin complex concentrate transfusion	Difference between initial INR and INR 24 hours after completion of transfusion
Secondary	Need for operative intervention as measured by need for neurosurgical procedure during the hospitalization	During duration of hospital stay, an expected average of 1 week	Need for operative intervention during hospitalization related to initial trauma
Secondary	Estimated blood loss during any neurosurgical procedure	During duration of hospital stay, an expected average of 1 week	Estimated blood loss during any neurosurgical interventions during the hospitalization
Secondary	Further transfusion needs as measured by number of units of blood/platelet/plasma products transfused during the hospitalization	During duration of hospital stay, an expected average of 1 week	Need for blood product transfusions during hospitalization
Secondary	In hospital mortality	During duration of hospital stay, an expected average of 1 week	Mortality during hospital stay
Secondary	Total hospital cost	During duration of hospital stay, an expected average of 1 week	Total cost of hospital stay based on hospital charges

1 to 10 of 12Source ClinicalTrials.gov

See all 12 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
37870112	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02429453

GET https://conductscience.org/api/trials/v1/NCT02429453/registered

API reference For AI assistants